CSL - CSL Ltd (ASX) Stock Forum

ASX:CSL is an Australian biotechnology company that specializes in the development and production of vaccines and plasma-based therapies. It is listed on the Australian Securities Exchange and is a popular stock among Aussie stock traders. Join our forum to discuss ASX:CSL and other Australian stocks with fellow traders.
annb0t
CSL News: ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization - 30th Apr 2024, 11:01pm
Replies
0
Views
36
annb0t
annb0t
annb0t
CSL News: Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) f - 24th Apr 2024, 9:05pm
Replies
0
Views
41
annb0t
annb0t
annb0t
CSL News: CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) f - 24th Apr 2024, 5:00pm
Replies
0
Views
23
annb0t
annb0t
annb0t
CSL News: CSL Limited (ASX:CSL) On An Uptrend: Could Fundamentals Be Driving The Stock? - 3rd Apr 2024, 9:13am
Replies
0
Views
69
annb0t
annb0t
annb0t
CSL News: An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 21% Undervalued - 25th Feb 2024, 11:00am
Replies
0
Views
85
annb0t
annb0t
annb0t
CSL News: Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatm - 23rd Feb 2024, 11:05pm
Replies
0
Views
59
annb0t
annb0t
annb0t
CSL News: Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³ - 13th Feb 2024, 5:21pm
Replies
0
Views
55
annb0t
annb0t
annb0t
CSL News: Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³ - 13th Feb 2024, 2:54pm
Replies
0
Views
68
annb0t
annb0t
annb0t
CSL News: CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of - 12th Feb 2024, 9:47am
Replies
0
Views
111
annb0t
annb0t
annb0t
CSL News: New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immun - 6th Feb 2024, 12:30am
Replies
0
Views
74
annb0t
annb0t
annb0t
CSL News: Are Medical Stocks Lagging Cardinal Health (CAH) This Year? - 1st Feb 2024, 1:40am
Replies
0
Views
50
annb0t
annb0t
annb0t
CSL News: CSL's (ASX:CSL) investors will be pleased with their decent 60% return over the last five years - 27th Jan 2024, 7:16am
Replies
0
Views
79
annb0t
annb0t
annb0t
CSL News: Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Conven - 17th Jan 2024, 12:00am
Replies
0
Views
75
annb0t
annb0t
annb0t
CSL News: Why Does China Remain Terrible at Soccer? Xi Jinping Has One Answer - 11th Jan 2024, 1:45am
Replies
0
Views
174
annb0t
annb0t
annb0t
CSL News: CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) - 4th Jan 2024, 12:00am
Replies
0
Views
83
annb0t
annb0t
annb0t
CSL News: CSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation - 22nd Dec 2023, 12:00am
Replies
0
Views
105
annb0t
annb0t
annb0t
CSL News: CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Sup - 22nd Dec 2023, 12:00am
Replies
0
Views
92
annb0t
annb0t
annb0t
CSL News: CSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance - 15th Dec 2023, 6:35am
Replies
0
Views
117
annb0t
annb0t
annb0t
CSL News: CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatme - 12th Dec 2023, 11:30am
Replies
0
Views
171
annb0t
annb0t
annb0t
CSL News: Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the - 29th Nov 2023, 12:05am
Replies
0
Views
91
annb0t
annb0t
You must log in or register to post here.

Share this page

Top Bottom